CDSCO has made pharmacovigilance compliance mandatory for pharmaceutical companies, requiring robust systems to monitor and report adverse drug reactions. The move aims to strengthen drug safety, improve post-marketing surveillance and prevent public health risks linked to unsafe medicines.